CUORIPS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,405 JPY | +0.74% |
|
-3.95% | +46.70% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 13 2.02K 17.84 | Sales 2023 | 38 5.91K 52.14 | Capitalization | 180M 28.03B 247M |
|---|---|---|---|---|---|
| Net income 2022 | -375M -58.34B -515M | Net income 2023 | -452M -70.32B -620M | EV / Sales 2022 * | - |
| Net cash position 2022 * | - 0 0 | Net cash position 2023 * | - 0 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | 43 |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 71.16% |
More Fundamentals
* Assessed data
| 1 day | +0.74% | ||
| 1 week | -3.95% | ||
| Current month | -0.87% | ||
| 1 month | -14.66% | ||
| 3 months | +39.55% | ||
| 6 months | +112.81% | ||
| Current year | +46.70% |
1 week
3 340.00
3 585.00
1 month
3 140.004 065.00
Current year
1 952.004 075.00
1 year
1 287.004 075.00
3 years
1 287.004 075.00
5 years
1 287.004 075.00
10 years
1 287.004 075.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 20-05-31 | |
Yoshiki Sawa
CTO | Chief Tech/Sci/R&D Officer | 68 | 21-07-31 |
Manabu Inoue
ADM | Chief Administrative Officer | 68 | 17-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ryohei Shimazaki
BRD | Director/Board Member | 65 | 20-11-30 |
| Chief Executive Officer | 65 | 20-05-31 | |
Manabu Inoue
ADM | Chief Administrative Officer | 68 | 17-06-30 |
Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q4 2023 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +46.70% | 180M | |
| -3.55% | 89.33B | |
| +4.08% | 41.19B | |
| -15.09% | 31.87B | |
| +53.68% | 24.52B | |
| -15.13% | 15.68B | |
| -8.63% | 12.34B | |
| -40.39% | 12.23B | |
| +6.22% | 8.83B | |
| -6.32% | 8.28B |
- Stock Market
- Equities
- 4894 Stock